Global Amitriptyline
Market, By Strength (10 mg tablets, 25 mg tablets, 50 mg tablets, 75 mg
tablets, 100 mg tablets, and 150 mg tablets), By Indication (Depression,
Nocturnal Enuresis, Migraine, Chronic Neuropathic Pain, and Others), by Distribution
Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by
Region (North America, Latin America, Europe, Asia Pacific, Middle East, and
Africa), is estimated to be valued at US$ 527.4 million in 2020 and is expected
to exhibit a CAGR of 5.3% during the forecast period (2020-2027), as
highlighted in a new report published by Coherent Market Insights.
The increasing R&D activities
focused on evaluating the efficiency of amitriptyline in various therapeutic
areas, is expected to drive the growth of the global amitriptyline market. For
instance, in April 2016, Boston Medical Center initiated phase 2 clinical study
to compare the effectiveness of amitriptyline versus placebo (inactive
medication) in treating chronic laryngitis. The study is expected to complete
in October 2022.
Global Amitriptyline Market –
Impact of Coronavirus (COVID-19) Pandemic
Since the COVID-19 virus outbreak
in December 2019, the disease has spread to over 100 countries across the globe
with the World Health Organization declaring it a public health emergency.
According to the World Health Organization’s report, manifestation of the
coronavirus disease (COVID-19) has resulted in more than 36.1 million infected
individuals worldwide as of October 7, 2020.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/4226
COVID-19 has affected the economy
in three main ways; by directly affecting production and demand, by creating
disruptions in distribution channel, and by its financial impact on firms and
financial markets. Due to nationwide lockdowns, several countries such as
India, China, UAE, Saudi Arabia, and others are facing problems with regards to
transportation of drugs from one place to another.
The coronavirus (COVID-19)
pandemic and resulting lockdowns in various countries across the globe have
impacted the financial status of businesses in all sectors. The private
healthcare sector has been impacted significantly by the pandemic. The
lockdowns have placed an economic burden on the private as well as public
healthcare sector.
Healthcare providers were facing
problems in investing additional manpower, equipment, consumables, and other
resources to ensure safety in hospitals, provide treatment to patients with
other diseases, and declining outpatient visits, etc.
Furthermore, pharmaceutical
companies are facing major challenges on various fronts due to the pandemic.
The major challenges include disruption in supply of raw materials required for
manufacturing drug formulations due to irregularities in transportation.
Moreover, distributors of drug products are experiencing irregular demand from
retailers.
Browse 36 Market Data Tables and
37 Figures spread through 178 Pages and in-depth TOC on “Global Amitriptyline
Market, By Strength (10 mg tablets, 25 mg tablets, 50 mg tablets, 75 mg
tablets, 100 mg tablets, and 150 mg tablets), By Indication (Depression,
Nocturnal Enuresis, Migraine, Chronic Neuropathic Pain, and Others), by
Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online
Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific,
Middle East, and Africa).
Browse Research
Report: https://www.coherentmarketinsights.com/market-insight/amitriptyline-market-4226
The global amitriptyline market
growth is expected to be driven by high prevalence of depression and
prescriptions of antidepressants. For instance, according to data published by
the American Psychological Association in 2017, there was a 64% increase in the
percentage of people using antidepressants between 1999 and 2014 in the U.S.
Key Takeaways of the Global
Amitriptyline Market:
The global amitriptyline market
is expected to exhibit a CAGR of 5.3% during the forecast period owing to the
increasing prevalence of depression among the population, which may facilitate
demand for amitriptyline.
Moreover, research institutes are
also engaged in conducting clinical trials which is contributing to growth of
the market. For instance, in September 2020, the University of California,
Davis commenced a clinical trial to assess the physiological and behavioral
mechanisms associated with amitriptyline in adult patients with functional
GERD-related symptoms. The study estimated to complete in December 2021.
Key players operating in the
global amitriptyline market are Accord Healthcare Inc., Mylan Pharmaceuticals
Inc., Sandoz Inc., Sun Pharmaceutical Industries Inc., Vintage Pharmaceuticals
Inc., Zydus Pharmaceuticals USA Inc., Watson laboratories Inc., and Torrent
Pharmaceuticals Ltd.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/4226
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
No comments:
Post a Comment